compuPharma Inc.
The first virtual drug application before the FDA
Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure. (New England Journal of Medicine 1999:341: 709-17.)
To take advantage of increased worldwide usage and reduce side effects place ANDA with FDA for 15 mg tablet with tradename Redactone and petition Dr. Pitt (coordinator of published study) to become involved in the new venture.
|
|
